Abstract 648P
Background
CBP-1019 is a globally first-in-class bi-specific ligand drug conjugate (Bi-XDC) that targets both FRα and TRPV6 with the payload of exatecan (DX-8951), developed by Coherent Biopharma. Preclinical studies have shown that CBP-1019 with a MW of only 3 KD can deliver more payloads than TOPO-I ADCs with a favorable safety profile, demonstrating a therapeutic window of 15-30 folds greater. Up to 90%-100% TGI was observed in PDX models at the dose of 50-75 mg/kg (equivalent to 4 - 6 mg/kg in human). We designed a phase I/II study to evaluate the safety and efficacy of CBP-1019 in pts with advanced solid tumors (NCT05830097). Currently, we reported the results from the phase I study.
Methods
In phase I study, an accelerated titration design was employed for the first two dose levels (1.0, 2.0 mg/kg Q2W), followed by a standard "3+3” design for the subsequent dose levels (3.0 - 6.0 mg/kg Q2W). Dose expansion would be conducted in selected dose levels. The primary endpoints included safety, MTD, RP2D and ORR.
Results
By 31st Mar. 2024, 22 pts were enrolled (1.0 - 4.0 mg/kg), with median age of 59 years. All pts were heavily prior treated with median 4 lines of treatment. DLT was not observed and MTD not yet reached. Most TRAEs were grade 1 or 2. The most commonly ≥grade 3 TRAEs mainly in neutrophil count decreased (27.3%), platelet count decreased (18.2%), white blood cell count decreased (13.6%), anemia (9.1%) and lymphocyte count decreased (9.1%). 4 pts have been treated for over 4 months (the longest treatment duration is over 7 months) without AEs of interstitial pneumonia or ophthalmic toxicity occurred. Among 13 efficacy evaluable pts ≥ 2.0 mg/kg dose, 2 ovarian cancer pts with confirmed PR (maximum target lesion reduction was 66.0% and 34.0%, respectively) and 9 with SD were observed. The exposure of CBP-1019 and DX-8951 increased with dose escalation, without accumulation of either substance after multiple doses.
Conclusions
CBP-1019 as the first-in-class bi-XDC globally, was well-tolerated at 1.0 - 4.0 mg/kg Q2W without DLTs or other common severe toxicities observed in ADCs. Preliminary antitumor activity was seen at ≥2 mg/kg dose.
Clinical trial identification
NCT05830097.
Editorial acknowledgement
Legal entity responsible for the study
Coherent Biopharma.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
630P - Debio 0123 + carboplatin (CP) for patients (pts) with advanced solid tumors: Safety, preliminary efficacy and determination of recommended phase II dose (RP2D)
Presenter: Hans Gelderblom
Session: Poster session 01
631P - Phase Ib expansion study of CX-5461 in patients with solid tumours and BRCA2 and/or PALB2 mutation
Presenter: Pamela Soberanis Pina
Session: Poster session 01
632P - Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 01
633P - First-in-human dose-escalation study of basroparib (STP1002) in patients with advanced-stage solid tumors
Presenter: Christopher Lieu
Session: Poster session 01
634P - First results from phase I/II study of CTS2190, a novel small-molecule inhibitor of type I PRMTs, in patients with advanced solid tumors
Presenter: Xiangdong Cheng
Session: Poster session 01
635P - The phase I dose-escalation study of TSN084, a multi-kinase inhibitor, in patients with advanced malignant tumors
Presenter: Jie Wang
Session: Poster session 01
636P - Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy
Presenter: Benjamin Kong
Session: Poster session 01
637P - AC699, a novel chimeric estrogen receptor degrader, in a phase I study in breast cancer
Presenter: Erika Hamilton
Session: Poster session 01
638P - Final results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center
Presenter: Apostolia Maria Tsimberidou
Session: Poster session 01
639P - Serial ctDNA profiling as a catalyst for tailored therapeutics in advanced cancer: Analysis of two precision medicine studies
Presenter: Sophie Cousin
Session: Poster session 01